Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | GC | P02774 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | RXRA | P19793 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15371109 | 0.92 | VDR (0.82) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL19461421 | 0.92 | VDR (0.82) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL10307536 | 0.92 | VDR (0.82) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL15371115 | 0.92 | VDR (0.82) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL10307541 | 0.92 | VDR (0.82) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL23359143 | 0.91 | VDR (0.81) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL12513502 | 0.91 | VDR (0.81) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL23359142 | 0.91 | VDR (0.81) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL12513499 | 0.91 | VDR (0.81) | VDRMAPTSREBF1SMN1; SMN2NR1I2 | |
| SCHEMBL13993786 | 0.90 | VDR (0.80) | VDRMAPTSREBF1SMN1; SMN2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115758-B2 | Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-10-03 | — | — | US | disclosed |
| EP-1210327-B1 | NEW VITAMIN D DERIVATIVES WITH CYCLIC SUBSTRUCTURES IN THE SIDE CHAINS, METHOD AND INTERMEDIATES FOR THEIR PRODUCTION AND THEIR USE IN THE PREPARATION OF MEDICAMENTS | SCHERING AG (DE) | 2006-01-18 | — | — | EP | disclosed |
| EP-1362848-A1 | Process for the preparation of vitamin D derivatives | Schering Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | STEINMEYER ANDREAS (US) | 2003-08-07 | — | — | US | disclosed |
| US-6603031-B1 | Active metabolites of vitamin D2 and vitamin D3 and their synthetic derivatives have a proliferation- inhibiting and differentiation-stimulating action on tumor cells and normal cells, | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1210327-A2 | NEW VITAMIN D DERIVATIVES WITH CYCLIC SUBSTRUCTURES IN THE SIDE CHAINS, METHOD AND INTERMEDIATES FOR THEIR PRODUCTION AND THEIR USE IN THE PREPARATION OF MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001007405-A2 | NEW VITAMIN D DERIVATIVES WITH CYCLIC SUBSTRUCTURES IN THE SIDE CHAINS, METHOD AND INTERMEDIATES FOR THEIR PRODUCTION AND THEIR USE IN THE PREPARATION OF MEDICAMENTS | SCHERING AKTIENGSELLSCHAFT (DE) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | CYP24A1, CYP2R1, VDR | VDR 3/4885MAPT 4518/4885SREBF1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.